BioNTech Expects Nearly $20 Billion In Covid Shot Sales; But Was The Guide High Enough?

 BioNTech stock popped early Tuesday after the Covid vaccine maker reported adjusted income of $14.30 per share on roughly $7.05 billion in sales.

On average, analysts polled by FactSet expected BioNTech (BNTX) to earn $12.21 per share and report $5.91 billion in sales.

In the year-earlier period, BioNTech lost $1.04 a share and posted $80 million in sales, based on exchange rates at the time. That was before the company's Pfizer (PFE)-partnered Covid vaccine launched.

For the year, BioNTech guided to 16 billion to 17 billion euros in sales of Covid vaccine, or roughly $18.5 billion to $19.7 billion in sales. Analysts called for adjusted earnings of $41.83 a share and $19.83 billion in sales.

https://www.investors.com/news/technology/biontech-stock-biontech-earnings-q3-2021/